The SAGE meeting of 23-25 October 2018 took place at the Centre International de Conference in Geneva. Available on this site you will find meeting information, background reading materials and presentations made at the meeting. The conclusions and recommendations of SAGE meeting are published in the WHO Weekly Epidemiological Record in English and French within two months of each SAGE meeting.
Meeting materials
Related
SAGE Yellow Book for October 2018
SAGE tracking record of recommendations and action points
Report of the AFRO Regional Immunization Technical Advisory Group Meeting (RITAG) - 29-30 June 2018, Kigali, Rwanda
Report of the PAHO regional Technical Advisory Group (TAG) on vaccine-preventable diseases - 10 July 2018, Washington D.C., USA
Report of the SEARO regional Immunization Technical Advisory Group (SEAR-ITAG) - 17 - 20 July 2018, New Delhi, India
Report of the WPRO regional Technical Advisory Group on Immunization and Vaccine-preventable Diseases - 19 - 22 June 2018, Manila, Philippines
Immunization in a Changing World From April-October 2018: What a difference 6 months makes - M. Friede
No background documents provided for this session.
Global Advisory Committee on Vaccine Safety (GACVS), 6–7 June 2018
Annotated IVIR-AC Agenda 2018 (draft) - 24 - 26 September 2018
Immunization and Vaccine related Implementation Research Advisory Committee (IVIR-AC) recommendations September 2018
Immunization Practices Advisory Commitee (IPAC) 12th Meeting - 11- 12 July 2018, Geneva, Switzerland
WHO’s 5th Product Development for Vaccines Advisory committee (PDVAC) meeting- 26 - 28 June 2018, Geneva, Switzerland
PDVAC background document: The potential role of the Controlled Human Infection Model (CHIM) in advancing licensure and introduction of next-generation O- antigen-based vaccines against Shigella- Cal MacLennan (BMGF) and Birgitte Giersing (IVR WHO)
PDVAC bacground document: WHO Preferred Product Characteristics for New Tuberculosis Vaccine
Report from Global Advisory Committee on Vaccine Safety (GACVS) - R. Pless (Recorded from June 2018 meeting)
Report from the Immunization and Vaccine related Implementation Research (IVIR) Advisory Committee - W. Orenstein
Report from Immunization Practice Advisory Committee (IPAC) - C. Morgan
Report from Product Development for Vaccines Advisory Committee (PDVAC) - D. Kaslow
Draft: 2018 Assessment report of the Global Vaccine Action Plan (GVAP)
Draft: 2018 Secretariat report of the Global Vaccine Action Plan (GVAP)
Regional reports on progress towards the GVAP RVAP Goals (annex to GVAP secretariat report)
National Immunization coverage scorecards estimates for 2017
Proposed Outline for a post-GVAP Global Immunization Strategy (2021-2030): Accelerating Universal Immunization Coverage by 2030
Summary of GVAP implementation progress review and recommendations for additional efforts - N. MacDonald
Process to develop a post-2020 Global Immunization Strategy 2021-2030 - P. Lydon
Pregnancy Research Ethics for Vaccines, Epidemis and New Technologies (PREVENT): Pregnant women and vaccines against emerging epidemic threats - Ehtics guidance for preparedness, research and response
WHO Guidance on Ethics & infectious disease outbreaks - A. Reis and M Guraiib
PREVENT initiative - Pregnant Women & Vaccines Against Emerging Epidemic Threats: Ethics Guidance for Preparedness, Research, & Response - R. Karron
Executive Summary for SAGE session on polio
16th Meeting of the SAGE Polio Working Group - Conclusions and recommendations: Note for the Record, 4-5 September 2018, Geneva, Swizterland
Appraisal of options for certification of global poliovirus eradication
Review of polio endemic countries - September 2018
Overview of the Global Polio Eradication Initiative - M. Zaffran
Executive summary for SAGE session on measles and rubella
Feasibility of Measles and Rubella Eradication - draft outline of report to the World Health Assembly (WHA)
Background Paper on Immunologic Response to Measles-Containing Vaccines (MCVs) and Yellow Fever (YF) vaccines when co-administered
Guidance to Increasing Population Immunity against Measles and Rubella, Global Immunization Division, Center for Global Health US Centers for Disease Control and Prevention
Meeting of the International Task Force for Disease Eradication, 10 November 2015, Atlanta, USA
Proceedings of the Global Technical Consultation to Assess the Feasibility of Measles Eradication
Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella, Vaccine journal 2011
Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia, The Lancet, August 2016
Chronovac Voyageur: A study of the immune response to yellow fever vaccine among infants previously immunized against measles,Vaccine journal, 2017
Session introduction Global update - A. Dabbagh
Feasibility of MR eradication - B. Moss
Co-administration of the YF vaccine with measles containing vaccines - J. Harris
Country classifications and guidance to increasing population immunity - S. Reef
Executive summary for SAGE session on HPV
Background paper for SAGE deliberations - HPV immunization schedules and strategies
Working Group on Human Papillomavirus (HPV) immunization - Report to SAGE
Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination, Vaccine journal, 2018
Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects, PLOS One journal, October 10 2017
Costs of Introducing and Delivering HPV Vaccines in Low and Lower Middle Income Countries: Inputs for GAVI Policy on Introduction Grant Support to Countries, PLOS One journal, Vol.9, Issue 6, June 2014
Costs of delivering human papillomavirus vaccination to school girls in Mwanza Region, Tanzania, BMC Medicine publication, 2012
A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool, BMC Medicine publication, 2012
HPV vaccines in females over 25 years
Worldwide burden of cancer attributable to HPV by site, country and HPV type, International Journal of Cancer (IJC), 2017
Global Market Study: HPV - September 2018
Session introduction and key questions - R. Aggarwal
Update on HPV vaccine introduction and programmatic perspective - T. Goodman
Overview of evidence regarding HPV immunization on different disease outcomes - A. Pollard
Forecast impact of different immunization strategies and screening scenarios towards cervical cancer elimination - M. Brisson
Conclusions and proposed recommendations by SAGE Working Group - R. Aggarwal
Executive summary for SAGE session on Ebola
Update with the development of Ebola vaccines and implications of emerging evidence to inform future policy recommendations
Interim recommendation Ebola vaccines
Session introduction and key questions - F. Were
Overview of Ebola epidemiology - D. Heymann
Update on candidate Ebola vaccines: available data on immunogenicity, efficacy and safety, timelines for licensure and Expanded Access/Compassionate Use experience - A.M. Henao Restrepo
Benefits and risk analysis of vaccination of pregnant women with rVSV-ZEBOV as part of Expanded Access/ Compassionate Use during Ebola outbreaks - J. Edmunds and C. Jarvis
Observed and forecasted impact of different Ebola candidate immunization strategies and targeted populations - A. Camacho
Proposed recommendations by SAGE Working Group - H. Rees and F. Were
Executive summary for SAGE session on lessons learned from diphtheria outbreaks
Update on Supply of Diphtheria Antitoxin and the Ad-Hoc Working Group on DAT
WHO position paper on diphtheria (August 2017)
Vaccination In Acute Humanitarian Emergencies: A Framework For Decision Making
Vaccine Decision Information System - Concept note for SAGE, Wilbert van Panhuis, MD PhD
WHO surveillance standards - diphtheria
Ensuring Sustained Protection Against Diphtheria: Replacing TT with Td vaccine, Wilbert van Panhuis, MD PhD
Introduction to session - F. Qadri
Case study: Diphtheria Outbreak in Cox Bazaar - S. Bahl
Global Opportunities and Gaps in Preventing Diphtheria Outbreaks - M. Gacic-Dobo
Country level risk assessment: example of possible approaches to guide country level actions - A.M. Henao Restrepo